Benzo[a]pyrene
Based on 10 publication(s) in Google Scholar
Benzo[a]pyrene shows lung carcinogenicity in animal models, and it is frequently used in chemoprevention studies.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.98%
- CAS No.: 50-32-8
- Formule: C20H12
- Masse moléculaire:252.31
-
Stockage:
Store at room temperature 3 years.
In solvent -80°C, 2 years , -20°C, 1 year
![Benzo[a]pyrene Chemical Structure](https://file.medchemexpress.com/product_pic/hy-107377.gif "Click to View Benzo[a]pyrene Chemical Structure")
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
-
Metabolism/Protease Compound Library
HY-L012
-
Natural Product Library
HY-L021
-
Anti-Cancer Compound Library
HY-L025
-
Clinical Compound Library
HY-L026
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
Anti-Lung Cancer Compound Library
HY-L075
-
Tumorigenesis-Related Compound Library
HY-L100
-
Anti-Cancer Natural Product Library
HY-L107
-
Plant-Sourced Natural Product Library
HY-L115
-
Human Metabolite Library
HY-L123
-
Mitochondrial Toxicity Compound Library
HY-L155
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Clinical Compound Library Plus
HY-L026P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Tibetan Medicine Compound Library
HY-L191
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Natural Product Diversity Scaffold Library
HY-L245
-
Mass Spectrometry Natural Product Library
HY-L262
Publications Citing Use of MedChemExpress (MCE) Benzo[a]pyrene
More- Allergy. 2026 Feb 27. [Abstract]
- Environ Pollut. 2026 Jul 15:401:128275. [Abstract]
- Cancer Cell Int. 2024 Jan 17;24(1):33. [Abstract]
- Ecotoxicol Environ Saf. 2026 May:316:120135. [Abstract]
- Ecotoxicol Environ Saf. 2026 May:316:120177. [Abstract]
- Int Immunopharmacol. 2025 Dec 29:170:116118. [Abstract]
- Mol Divers. 2026 Apr 19. [Abstract]
- Neurotoxicology. 2021 Sep:86:78-84. [Abstract]
- Vascul Pharmacol. 2026 Mar:162:107589. [Abstract]
- Research Square Preprint. 2022 Feb.
Customer Validation & Images
-
Cell Imaging/Staining
-
WB
-
ELISA
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
Voir tous les produits spécifiques à Isoform Endogenous Metabolite
More
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MCF7 | EC50 |
2.7 μM
Compound: 2
|
Agonist activity at aryl hydrocarbon receptor in human MCF7 cells after 24 hrs CYP1A1-dependent EROD assay
Agonist activity at aryl hydrocarbon receptor in human MCF7 cells after 24 hrs CYP1A1-dependent EROD assay
|
[PMID: 20060304] |
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.
Benzo[a]pyrene (B[a]P) can be used to create lung tumor models. The bioavailability of Benzo[a]pyrene in rats is 10%, with a half-life of 16.6 hours. In female A/J mice, compared to the vehicle group, the 1.0 mg Benzo[a]pyrene treatment group shows statistically significant differences at 7 weeks, indicating that Benzo[a]pyrene-induced lung tumorigenesis is dose-dependent. The incidence of hyperplasia in female mice treated with 0.25, 0.50, and 1.0 mg Benzo[a]pyrene is significantly higher than in the vehicle group, and the adenoma incidence in the 1.0 mg Benzo[a]pyrene group is also significantly increased. Additionally, the multiplicity of hyperplasia in the 0.50 or 1.0 mg Benzo[a]pyrene treatment groups and the multiplicity of adenomas in the 1.0 mg group are significantly higher than in the vehicle group. Benzo[a]pyrene significantly increases the incidence of hyperplasia and adenomas in female A/J mice in a dose-dependent manner. On average, Benzo[a]pyrene induces the formation of 9.38±1.75 tumors, with an average tumor burden of 19.53±3.81 mm3. Administration of Benzo[a]pyrene also significantly decreases the levels of cAMP in the tumor and surrounding lung tissue and increases the expression levels of the PDE4D gene[1][2].
Administration: 50 mg/kg• p.o. • twice a week (1st and 4th day) for four successive weeks
(2) All procedures were performed at temperatures ranging between 0 and 4°C.
(3) At the end of the experimental period, the animals were sacrificed. Lung tissues were isolated, washed in ice cold 1.15 % KCl and homogenized.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 50-32-8
-
Appearance Solid
-
Masse moléculaire 252.31
-
Formule C20H12
-
Color Light yellow to yellow
-
SMILES
C12=C(C=C3)C=C(C=CC=C4)C4=C1C=CC5=CC=CC3=C25
-
Synonyms
3,4-Benzopyrene
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Store at room temperature 3 years
In solvent -80°C 2 years -20°C 1 year
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
Allergy
Identification of Key Genes Associated With Epithelial Barrier Dysfunction by Comprehensive Analysis and Experimental Validation. [Abstract]2026 Feb 27. PMID: 41755794 -
Environ Pollut
Machine learning and multi-dimensional transcriptomics reveal the key molecular network of benzo(a)pyrene/NNK in promoting laryngeal cancer and develop prognostic models. [Abstract]2026 Jul 15:401:128275. PMID: 42107864 -
Cancer Cell Int
USP29 activation mediated by FUBP1 promotes AURKB stability and oncogenic functions in gastric cancer. [Abstract]2024 Jan 17;24(1):33. PMID: 38233848
Benzo[a]pyrene purchased from MedChemExpress. Usage Cited in: Cancer Cell Int. 2024 Jan 17;24(1):33. [Abstract]
Representative images showed gross morphology of stomachs harboring Benzo[a]pyrene (BaP)-induced tumors (50 mg/kg; i.g.; twice a week for 6 weeks) from wildtype and Usp29−/− mice.
-
Ecotoxicol Environ Saf
Benzo[a]pyrene exacerbates bone destruction by inhibiting Treg differentiation, impairing Treg function and promoting osteoclastogenesis in rats with collagen-induced arthritis. [Abstract]2026 May:316:120135. PMID: 41980281 -
Ecotoxicol Environ Saf
Integrating network toxicology and experimental validation to elucidate the molecular mechanism basis of chondrotoxicity of Benzo[a]pyrene in osteoarthritis. [Abstract]2026 May:316:120177. PMID: 42034589 -
Int Immunopharmacol
TNFAIP3, PADI4, and CXCR4 as biomarkers of neutrophil extracellular traps in severe asthma. [Abstract]2025 Dec 29:170:116118. PMID: 41475137
Benzo[a]pyrene purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2025 Dec 29:170:116118. [Abstract]
SYTOX Green staining to visualize NETs formation in neutrophils after Benzo[a]pyrene (BaP) (10 μM; 24 h) exposure.
Benzo[a]pyrene purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2025 Dec 29:170:116118. [Abstract]
Western blot analysis detecting H3Cit levels in neutrophils treated with different Benzo[a]pyrene (BaP) (5-10 μM; 24 h) concentrations. Benzo[a]pyrene (BaP) increased NETs generation in a dose-dependent manner.
Benzo[a]pyrene purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2025 Dec 29:170:116118. [Abstract]
The levels of MPO-DNA complexes in the neutrophil culture supernatants were measured following transfection with siRNAs targeting PADI4. Benzo[a]pyrene (BaP) (100 μg/mL; 24 h) markedly promoted NETs formation in HL60-induced neutrophil models.
-
Mol Divers
Multi-omics, molecular modeling and experimental analysis of carcinogen benzo(a)pyrene promoting the progression of laryngeal cancer. [Abstract]2026 Apr 19. PMID: 42001354 -
Neurotoxicology
The use of tocofersolan as a rescue agent in larval zebrafish exposed to benzo[a]pyrene in early development. [Abstract]2021 Sep:86:78-84. PMID: 34273383
Benzo[a]pyrene purchased from MedChemExpress. Usage Cited in: Neurotoxicology. 2021 Sep:86:78-84. [Abstract]
Under all lighting conditions, Benzo[a]pyrene (BaP) (5 μM; from 5 hpf until 5 dpf) significantly reduced the activity level of zebrafish compared to the control group.
-
Vascul Pharmacol
Benzo[a]pyrene exacerbates atherosclerosis by upregulating SPP1 to promote macrophage inflammation and lipid dysregulation: An integrated network toxicology, RNA-seq, and experimental validation study. [Abstract]2026 Mar:162:107589. PMID: 41747816 -
Solvant et solubilité
DMSO : 16.67 mg/mL (66.07 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.67 mg/mL (6.62 mM); Clear solution
This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 1.67 mg/mL (6.62 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 1.67 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 1% CMC-Na/saline water
Solubility: 5 mg/mL (19.82 mM); Suspended solution; Need ultrasonic and warming and heat to 50°C
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
Female A/J mice are randomized into eight groups (n=8): (i) control; (ii)Benzo[a]pyrene (B(a)P)+vehicle (methocel); (iii) Benzo[a]pyrene+roflumilast 1 mg/kg; (iv) Benzo[a]pyrene+roflumilast 5 mg/kg; (v) Benzo[a]pyrene+aerozolie phosphate-buffer saline (PBS); (vi) Benzo[a]pyrene+aerosolize budesonide 2.25 mg/mL; (vii) Benzo[a]pyrene+aerosolized budesonide 2.25 mg/mL+roflumilast 1 mg/kg; and (viii) Benzo[a]pyrene+aerosolize budesonide 2.25 mg/mL+roflumilast 5 mg/kg groups. A single dose of Benzo[a]pyrene in corn oil is given intraperitoneally once at 100 mg/kg body weight. Roflumilast (1 or 5 mg/kg) is started 2 weeks after Benzo[a]pyrene. It is continued for 26 weeks (3 days/week) via oral gavage. Mice in the Benzo[a]pyrene+vehicle group are treated with an equal volume of methocel as solvent control. Aerosolizing budesonide is administrated by inhaling route as an aerosol at a dose of 2.25 mg/mL for 2 min per application at 2 weeks after Benzo[a]pyrene. It is continued for 26 weeks (5 days/week). PBS is also used as solvent control by inhaling route after Benzo[a]pyrene administration in the Benzo[a]pyrene+PBS group. Mice are killed at 28 weeks after exposure to Benzo[a]pyrene. Their lungs are excised and stored at -70 °C[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
-
Fiche technique (285 KB)
-
SDS (761 KB)
- English - EN (761 KB)
- Français - FR (761 KB)
- Deutsch - DE (761 KB)
- Norwegian - NO (761 KB)
- Español - ES (761 KB)
- Swedish - SV (761 KB)
- Italian - IT (761 KB)
- Korean - KR (761 KB)
- Portuguese - PT (761 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Saeko Onami, et al. Dosimetry for lung tumorigenesis induced by urethane, 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK), and benzo[a]pyrene (B[a]P) in A/JJmsSlc mice. J Toxicol Pathol. 2017 Jul; 30(3): 209–216. [Content Brief]
[2]. Yeo CD, et al. Roflumilast treatment inhibits lung carcinogenesis in benzo(a)pyrene-induced murine lung cancer model. Eur J Pharmacol. 2017 Oct 5;812:189- [Content Brief]
[4]. Anandakumar P, et al. Capsaicin inhibits benzo(a)pyrene-induced lung carcinogenesis in an in vivo mouse model. Inflamm Res. 2012 Nov;61(11):1169-75. [Content Brief]
[5]. Kasala ER, et al. Benzo(a)pyrene induced lung cancer: Role of dietary phytochemicals in chemoprevention. Pharmacol Rep. 2015 Oct;67(5):996-1009. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.9634 mL | 19.8169 mL | 39.6338 mL | 99.0845 mL |
| 5 mM | 0.7927 mL | 3.9634 mL | 7.9268 mL | 19.8169 mL | |
| 10 mM | 0.3963 mL | 1.9817 mL | 3.9634 mL | 9.9084 mL | |
| 15 mM | 0.2642 mL | 1.3211 mL | 2.6423 mL | 6.6056 mL | |
| 20 mM | 0.1982 mL | 0.9908 mL | 1.9817 mL | 4.9542 mL | |
| 25 mM | 0.1585 mL | 0.7927 mL | 1.5854 mL | 3.9634 mL | |
| 30 mM | 0.1321 mL | 0.6606 mL | 1.3211 mL | 3.3028 mL | |
| 40 mM | 0.0991 mL | 0.4954 mL | 0.9908 mL | 2.4771 mL | |
| 50 mM | 0.0793 mL | 0.3963 mL | 0.7927 mL | 1.9817 mL | |
| 60 mM | 0.0661 mL | 0.3303 mL | 0.6606 mL | 1.6514 mL |
Benzo[a]pyrene Related Classifications
HY-107377 Related Classifications
Powered by Bioz